Compare D Wave Quantum Inc (QBTS) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D Wave Quantum Inc vs Revvity Inc — how do they compare? D Wave Quantum Inc trades at $17.35 (market cap $6.59B), while Revvity Inc trades at $110.67 (market cap $12.33B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.25% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals.
| QBTS | RVTY | |
|---|---|---|
Market Cap | $6.59B | $12.33B |
Sector | Technology | Technology |
52-Week High | $44.78 | $117.75 |
52-Week Low | $12.98 | $82.26 |
Enterprise Value | $6.05B | $14.82B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QBTS trades at $16.73, showing no change in the last 24 hours. The stock is technically bearish with key support at $16 and resistance at $17. Fundamentally, the company reported a net loss of $355.06 million on $24.59 million revenue in 2025, with a negative net income margin of -2,957.23%. Recent news highlights D-Wave's dual-platform quantum computing approach and a recent transfer of its stock listing to Nasdaq (Business Wire, July 14, 2026).
Despite unanimous analyst buy ratings and a $39.86 consensus price target implying significant upside, QBTS faces substantial execution risks. High cash burn, negative profitability, and intense competition in the emerging quantum computing sector present challenges. The stock's appeal hinges on future revenue growth materializing from current commercial partnerships and technological advancements.
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
